The WOMAC Osteoarthritis Index: A Comprehensive Guide for Researchers and Clinicians

By ResRef

Published 2026-11-10

An expert guide to the WOMAC index for assessing pain, stiffness, and function in osteoarthritis. A key tool for researchers and clinicians

Introduction to the WOMAC osteoarthritis

The Western Ontario and McMaster Universities Osteoarthritis Index, universally known as WOMAC, is a patient-reported outcome measure and a cornerstone in rheumatology and orthopedics. A team led by N. Bellamy, W.W. Buchanan, C.H. Goldsmith, J. Campbell, and L.W. Stitt developed the index in 1982 and validated it in 1988. The WOMAC specifically evaluates pain, stiffness, and physical function in patients with hip and knee osteoarthritis. Clinicians and researchers also widely use it for other musculoskeletal conditions due to its robust psychometric properties and clinical relevance. With over 10,000 citations, the global medical community recognizes the WOMAC as a gold standard for assessing osteoarthritis severity, particularly in clinical trials. This article, therefore, provides a detailed overview of the WOMAC index, its scoring, its validation, and its critical role in both clinical practice and research.

Key Features of the WOMAC osteoarthritis

Clinicians highly regard the WOMAC for its comprehensive yet practical structure, which thoroughly captures the patient's experience. Consequently, they must understand its core features to ensure effective implementation.

Purpose

The main purpose of the WOMAC is to evaluate the key symptoms of osteoarthritis of the hip and knee, including pain, stiffness, and limitations in physical function. This makes it an indispensable tool for assessing the health status and overall impact of OA on patients' lives.

Target Population

The WOMAC is validated for use in adults aged 18 and older who have been diagnosed with osteoarthritis, including:

Young Adults (18-24 years)

Middle-Aged Adults (25-44 years)

Older Adults (45-64 years)

Seniors (65+ years)

While it has been used in adolescent populations, further validation is needed for this age group.

Comprehensive Questionnaire Structure and Symptom Clusters

The standard WOMAC questionnaire contains 24 items, which are logically organized into three critical sub-domains:

Pain (5 items): This section assesses the severity of pain during specific activities such as walking, using stairs, and even while in bed or sitting.

Stiffness (2 items): This section measures the severity of stiffness, specifically after waking in the morning and later in the day.

Physical Function (17 items): This is the largest section, evaluating the degree of difficulty a patient has with a wide range of daily activities, from using stairs and standing up from a seated position to performing various household duties.

Scoring and Interpretation

Standardized scoring for the WOMAC index provides a clear and comparable measure of a patient's condition.

Response Scale: The most common version uses a 5-point Likert scale, where patients rate their symptoms from 0 (None) to 4 (Extreme).

Calculating Scores: Scores are calculated for each of the three subscales by summing the ratings of the items within them.

Total Score: A total WOMAC score is derived by summing the scores of all 24 items, resulting in a range from 0 to 96.

Interpretation: A higher score on any subscale or on the total score indicates worse symptoms, greater stiffness, and more severe functional limitations. There are no universal cut-off scores; instead, the severity is judged based on the score itself.

Normalization: For standardized comparison, raw scores are often normalized to a scale of 0-100 by multiplying each subscale score by 1.04.

Administration

The efficient WOMAC questionnaire takes patients only 5 to 10 minutes to complete. It supports self-administration in multiple formats—including paper, digital (online), or an in-person interview. Importantly, administrators require no special training to conduct the assessment.

Clinical and Research Applications

The WOMAC serves multiple crucial roles in both clinical practice and research settings for osteoarthritis management.

Screening: It is an effective tool for screening patients to assess the severity of their OA symptoms.

Monitoring: The index is invaluable for monitoring a patient's condition over time and tracking their response to various treatments, such as medication, physical therapy, or surgery.

Treatment Planning: By identifying which domains (pain, stiffness, or function) are most affected, the WOMAC helps clinicians tailor treatment plans to the individual patient's needs.

Research: The WOMAC is considered the gold standard for use as a primary endpoint in clinical trials for new osteoarthritis therapies.

Languages and Availability

The WOMAC is available in multiple languages, including:

English

French

Spanish

Mandarin Chinese

Reliability and Validity

Clinicians and researchers widely use the WOMAC in clinical trials because of its high reliability and validity.

Reliability: The scale demonstrates excellent internal consistency, with Cronbach's alpha values ranging from 0.82 to 0.96, depending on the specific subscale being measured.

Validation Studies: The WOMAC has been extensively validated since its original validation study. It has been translated and validated in numerous languages and for diverse populations, including a Finnish version and an Arabic version. The short form has also undergone rigorous validation.

Other Versions

To meet different clinical and research needs, the researchers have developed several versions of the WOMAC:

WOMAC Short Form: A condensed version with 11 items is available, specifically designed for patients with hip osteoarthritis.

WOMAC 3.1: This version offers flexibility in response formats, including the standard 5-point Likert Scale, a 100-mm Visual Analog Scale (VAS) suitable for visual-based research, and a 0–10 Numeric Rating Scale (NRS). The NRS format has the advantage of offering up to 22% higher sensitivity in detecting subtle changes in symptoms.

Limitations

Despite its strengths as the gold standard, the WOMAC has a few limitations to consider:

Self-Report Measure: Since it is based on patient self-report, scores can be influenced by individual perception, mood, and pain tolerance.

Social Desirability Bias: Respondents may underreport the severity of their symptoms to present themselves in a more positive light.

Cultural Bias: The phrasing of questions related to daily activities may not be equally relevant across all cultures, which could introduce bias.

Cost and Accessibility

The WOMAC is a proprietary, paid instrument. A license is required for its use.

Additional Resources

Licensing and Official Information: To learn more about the WOMAC or to obtain a license for its use, please visit the official website.

Access to the Questionnaire PDF: While proprietary, examples of the questionnaire can be found here: Example PDF 1 and Example PDF 2.

Original Validation Study.

Inquiries: For further inquiries, you can contact the primary author, Dr. N. Bellamy, at nicholas.bellamy@uq.edu.au.

Further Reading: For additional resources and studies on the WOMAC, consult the Shirley Ryan AbilityLab page on the index.

Frequently Asked Questions (FAQ)

What is the WOMAC index used for?

The WOMAC is used to evaluate pain, stiffness, and physical function in patients with osteoarthritis, especially of the hip and knee.

How long does it take to complete the WOMAC?

It is a brief questionnaire that typically takes between 5 and 10 minutes for a patient to complete.

Is the WOMAC free to use?

No, the WOMAC is a proprietary instrument and requires a paid license for use.

How is the WOMAC scored?

It uses a 0-4 Likert scale for 24 items, yielding a total score from 0 to 96. Higher scores indicate worse symptoms and functional impairment.

A word from ResRef

The WOMAC is a well-validated, widely used tool for assessing osteoarthritis severity, particularly in hip and knee OA. It is recommended by major rheumatology and orthopedic guidelines. It is the gold standard for OA clinical trials and rehabilitation monitoring.

References

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833-40. PMID: 3068365. Link

Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J., & Stitt, L. (1989). A study of the reliability and validity of a self-administered new health status measure for clinical trials in osteoarthritis of the hip and knee. Current Medical Research and Opinion, 11(7), 449-456. Link

Bellamy N, Buchanan WW. A preliminary evaluation of the dimensionality and clinical importance of pain and disability in osteoarthritis of the hip and knee. Clin Rheumatol. 1986 Jun;5(2):231-41. doi: 10.1007/BF02032362. PMID: 3731718. Link

Jinks, Clare∗; Jordan, Kelvin; Croft, Peter. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 100(1):p 55-64, November 2002. | DOI: 10.1016/S0304-3959(02)00239-7. Link